

25th May 2013, Saturday

Session 5
Roundtable 2: Fenofibrate in Diabetic Eye Disease
Chairs: Massimo Porta and Peter Scanlon

- 9.00-9.15 Simon Harding: Evidence from clinical trials
9.15-9.35 Rafael Simo: Potential mechanisms
9.35-9.50 Paul Dodson: Implications in clinical practice
9.50-10.00 Discussion

Session 6:
New Insights for Treatment of Diabetic Retinopathy
Chairs: Cristina Hernández and Edoardo Midena

- 10.00-10.15 Effect of fenofibrate on retinal neurodegeneration in DB/DB mice. L. Corraliza, P. Bogdanov, A.R. Rodrigues-Carvalho, J. Garcia-Arumí, C. Hernández, R. Simó
10.15-10.30 Beneficial effects of somatostatin in cellular viability of rcg5 cells and retinal explants under diabetic conditions: possible role of protein tyrosine phosphatase 1B. Ana I Arroba, Deborah J Burks, Cristina Hernández-Pascual, Rafael Simó and Angela M Valverde
10.30-10.45 The neuroprotective drugs somatostatin and brimonidine do not show adverse effects on human retinal pericytes. T. Lopatina, E. Beltramo, M. Porta
10.45-11.00 Novel nonpeptide superoxide dismutase mimetics attenuate hydrogen peroxide-induced damage to retinal ganglion cells and human retinal pericytes. A. Oknianska, U. Popowska, M. Gorska, N. Knap, A. Daca, S.P. Harding, M. Wozniak
11.00-11.15 A shift in the balance of VEGF and CTGF by bevacizumab causes the angio-fibrotic switch in proliferative diabetic retinopathy. M. Dallinga, I. Klaassen, R.J. Van Geest, S.Y. Lesnik-Oberstein, R. Goldschmeding, C.J.F. Van Noorden, R.O. Schlingemann
11.15-11.45 Coffee

Session 7
The Diabetic Eye
Chairs: Elizabeth Agardh and Luis Arias

- 11.45-12.00 Estimating the interval preceding diagnosis of type 2 diabetes from the time-course of retinopathy prevalence. M. Porta, G. Curletto, E. Coppo, A. Raviolo, E. Sitia, S. Albani, P. Dalmasso
12.00-12.15 Baseline predictors of 3-year responses to ranibizumab and laser photocoagulation therapy in patients with visual impairment due to diabetic macular oedema. V. Chong, P. Mitchell
12.15-12.30 Patient-reported visual function in diabetic macular oedema: 36-month results from the RESTORE extension study. P. Massin, P. Mitchell, J. Petrillo, C. D. Coon, A. Ferreira, N. Bressler

- 12.30-12.45 An evaluation of ophthalmic photographic diabetic review (OPDR) with two fields digital photography for diabetic maculopathy (M1) and 4 year follow-up. H. Fellows, M. Shah, A. Hamid, L. Quant, M. Clarke, P.M. Dodson
12.45-1.00 Clinical and demographic features of patients with diabetic macular oedema. F. Afshar, D. Baumgardt, C. Bailey
1.00 Best poster prize ceremony and closing remarks Massimo Porta

TIMING

The meeting will be on 23rd, 24th and 25th May 2013.

LOCATION

The meeting venue is the World Trade Center Barcelona (WTCB) Moll de Barcelona s/n. Edificio Este 08039 Barcelona, Spain

Getting to the WTCB

The WTCB can be reached easily by public transport. Bus 20, 21,36, 64, 94, 120, N0, N6. Metro lines 2 (Paral·lel) and 3 (Drassanes)



GALA DINNER

The Gala Dinner of the 23rd Meeting EASDec will take place in Port Vell (WTCB) on Friday 24th May at 7,30 for 8 pm.

MAIN SPONSORS:



SECRETARIA TÈCNICA:

GÒTIC

Avda. Portal de l'Àngel, 7 Àtic P
08002 Barcelona
Tel. 93 317 84 44 / 626 21 42 73
Fax. 93 317 86 82
E-mail: gotic@gotic-congres.com
www.gotic-congres.com

EASDec 2013
23rd Meeting

Barcelona
23rd-25th May 2013



Welcome



Rafael Simó
Chairman,
Local Organizing
Committee

On behalf of the Local Organizing Committee I am delighted to welcome you to the EASDec Annual Meeting 2013 in Barcelona. In this our 23rd Meeting we will present what we believe to be exciting new findings in both clinical and basic research into diabetic retinopathy and other diabetic eye associated diseases. In addition, it provides a good opportunity for us to exchange news and opinions, and to find out other research developments.

We hope you will enjoy your stay in Barcelona and find sufficient time to experience the Mediterranean atmosphere of our city.

BOARD OF THE EASDec

President: Massimo Porta

Vice-President: Simon Harding

Secretary: Tunde Peto

Treasurer: Rafael Simó

EASDec 2013 Programme

The entire conference, including the Opening ceremony and the dinner will be held at the WTCB

23rd May 2013, Thursday

“Satellite Symposium”: Spanish Society of Retina and Vitreous (SERV) (Supported by Novartis Spain)

4.00 – 7.00 New perspectives in the diagnosis and treatment of Diabetic Macular Oedema

Chairs: José García-Arumí and Rafael Simó

The official programme of EASDec starts with:

7.00 Opening ceremony followed by refreshments

24th May 2013, Friday

8.30 – 9.00 Registration

9.00 Introduction and welcome Rafael Simó

Session 1 Roundtable 1: New Perspectives in the Treatment of Diabetic Macular Oedema

Chairs: Jose García-Arumi and Gabriele E. Lang

9.15-9.35 Diabetologists' view: Javier Salvador, President of the Spanish Society of Endocrinology

9.35-9.55 Ophthalmologists' view: Pascale Massin

9.55-10.15 Discussion and chairman summary

10.15-10.30 Overexpression of hemopexin in the diabetic eye: a new pathogenic candidate for diabetic macular oedema. M. García-Ramírez, C. Hernández, R. Simó

10.30-10.45 Development of a new blood-retinal barrier model in vitro. A. Van der Wijk, J. Wisniewska-Kruk, I. Klaassen, R.O. Schlingemann

10.45-11.00 Molecular characterisation of the inner blood-retinal barrier in the akimba mouse, a new model of diabetic retinopathy. I. Klaassen, J. Wisniewska-Kruk, I.M.C. Vogels, C.M. Lai, C.J.F. Van Noorden, R.O. Schlingemann, E.P. Rakoczy

11.00-11.20 In memoriam Anne Katrin Sjolie presented by Massimo Porta
Best abstract prize: The role of plasmalemma vesicle-associated protein in blood retinal barrier permeability. J. Wisniewska-Kruk, I. Klaassen, I.M.C. Vogels, C.J.F. Van Noorden, R.O. Schlingemann

11.20-11.45 Coffee/tea, exhibitions

Session 2 Laboratory and Clinical Biomarkers of Diabetic Retinopathy

Chairs: Reiner Schlingemann and Jose Cunha-Vaz

11.45-12.00 Aqueous humor biomarkers of retina macroglia activation in diabetic patients. S. Vujosevic, M. Berton, S. Bini, A. Micera, G. Esposito, O. Kotsafti, E. Midena

12.00-12.15 Retinal inflammation biomarkers in patients with diabetic retinopathy. E. Midena, G. Midena, S. Bini, M. Berton, R. Parrozzani, O. Kotsafti, S. Vujosevic

12.15-12.30 Microaneurysm turnover predicts risk of development of clinically significant diabetic macular oedema. L. Ribeiro, S. Nunes, J. Cunha-Vaz

12.30-12.45 Microaneurysm-count as a predictor of progression of retinopathy in patients with type 1 diabetes? M. L. Rasmussen, R.B. Pedersen, T. Peto, J. Grauslund

12.45-1.00 Patterns of progression in diabetic retinopathy: correlation between phenotypes and genotypes. S. Nunes, C. Lobo, L. Ribeiro, I. Pires, M.J. Simões, C. Faro, J. Cunha-Vaz

1.00-1.15 Obstructive sleep apnea is associated with sight threatening retinopathy and predicts the development of preproliferative and proliferative retinopathy in patients with type 2 diabetes: a longitudinal analysis. A. Tahrani, P. Dodson, A. Ali, Q. Altaf, H. Wharton, N. T. Raymond, M. J. Stevens

1.15-3.00 Lunch and Poster Session

Session 3 Poster Session

Moderators: Tunde Peto and Anna Boixadera

Screening

- Diabetic retinopathy screening at a UK district general hospital. F. Blain, S. Shafquat
- Is it safe to increase diabetic retinopathy screening interval in patients with no/background diabetic retinopathy? H. Chambers,

- S.B. Balu, H.W. Wharton, P.M.D. Dodson, JMG. Gibson
- Epiretinal membrane in diabetic retinopathy screening. N. Bilkhu, A.D. Wright, A. Farnsworth, S. Osei-Amoako, P.M. Dodson
- Is arbitration of all abnormal grades valuable in retinopathy grading quality assurance? L. Quant, A.P. Mills, A. Hamid, H. Wharton, M. Clarke, P.M. Dodson
- Evaluation of automated image analysis software for the detection of diabetic retinopathy to reduce the ophthalmologist workload. E. Soto-Pedre, A. Navea, J. Morales, S. Millan, M.C. Hernaez-Ortega, P. Perez, M.C. Desco
- Review of change in referral rates to hospital eye services from a population based diabetic retinopathy screening service during the initial six years of service delivery. M. Morgan, M. Murphy
- Are diabetic retinopathy virtual clinics safe? O. Giasin, J. Myerscough, C. James, Y. Osoba
- Relationship between time from diagnosis of diabetes to screening and grading outcome. S. Aldington, I.M. Stratton, M. Histed, P. H. Scanlon
- Accuracy of glaucoma suspect referrals from diabetic retinopathy screening. T. Peto, K. Balaskas, R. Puertas
- NHS Diabetic Eye Screening Programme on-line Test and Training (TAT): past, present and future. S. Aldington, I.M. Stratton, D.J. Taylor, P.H. Scanlon
- The influence risk communication tools on diabetes self management. N. Al-Athamneh, J. Sturt, I.M. Stratton, A. Lindenmeyer, P.H. Scanlon

Basic Research

- Tear fluid proteomics multimarkers for diabetic retinopathy screening. A. Csutak, ZS. Torok, T. Peto, E. Csosz, A.M. Molnar, J. Tozser, A. Hajdu
- Role of vascular endothelium growth factor (VEGF) and renin-angiotensin systems in pathogenesis diabetic retinopathy. D. Lipatov, J.E. Bautina, M.V. Shestakova, A.G. Kuzmin, T.A. Chistjakov
- VEGF levels in plasma in relation to platelet activation, glycaemic control and microvascular complications in type 1 diabetes mellitus. R. Schlingemann, C.J.F. Van Noorden, J.C.M. Meijers, W.M. Wiersinga

Diabetic Macular Oedema

- Macular function: better than visual acuity for assessing diabetic maculopathy? A. Raj, J.N. Sahni, C. Campa, G. Czanner, R. Hagan, S.P. Harding
- RELIGHT- ranibizumab treatment of diabetic macular oedema with bimonthly monitoring after initial treatment. I. Pearce, The RELIGHT Study group
- Automated detection of leakage sites in fundus fluorescein angiography for diabetic maculopathy. M.T. Kwong, Y. Zheng, D. Parry, J.N. Sahni, A. Raj, S.P. Harding

Epidemiology

- Sixteen-year incidence of diabetic retinopathy and proliferative diabetic retinopathy in a nationwide cohort of young Danish type 1 diabetic patients. R. B. Pedersen, M.L. Rasmussen, T. Peto, J. Grauslund

- Non-Swedish origin may be a risk factor for diabetic retinopathy at diagnosis in Scania, Sweden, in 2008-2012. C. Gustavsson, M. Dorkhan, L. Groop
- Staging of diabetic retinopathy upon initial presentation in Saudi Arabia. R.M. Gandour, S. Waheeb, I.A. Alhabli, A.K. Baothman
- The effects of combined therapy with metformine and sulfonyleurea on clinical characteristics of metabolic syndrome in type 2 diabetes mellitus. M. Carcani, S. Carcani, M. Keci

Session 4 Pathophysiology of Diabetic Eye Disease

Chairs: Alan Stitt and Toke Bek

- 3.00-3.15 Loss of protein tyrosine phosphatase 1b increases IGF-i receptor tyrosine phosphorylation but does not rescue retinal defects in IRS2-deficient mice. Angela M. Valverde, Jesús Revuelta-Cervantes, Lorena Menes, Águeda González-Rodríguez, Virginia Pardo, Pedro de la Villa, Deborah J. Burks, Ana I. Arroba
- 3.15-3.30 Morphological and functional characterisation of retinal neurodegeneration in DB/DB mice. P. Bogdanov, L. Corraliza, A.R. Rodrigues-Carvalho, J. Garcia-Arumí, R. Simó, C. Hernández
- 3.30-3.45 Mesenchymal stem cell-derived microvesicles induce pericyte destabilisation in diabetic-like conditions. E. Beltramo, E. Berrone, T. Lopatina, M. Porta
- 3.45-4.00 Vitreous TIMP-1 levels associate with neovascularisation and TGF-β2 levels in the clinical course of proliferative diabetic retinopathy. I. Vogels, R.J. Van Geest, I. Klaassen, S.Y. Lesnik-Oberstein, R. Goldschmeding, C.J.F. Van Noorden, R.O. Schlingemann

4.00-4.45 Eva Kohner lecture:
Francesco Bandello
Introduced by Simon Harding

4.45-5.30 Annual General Meeting
Moderator: Tunde Peto

Gala dinner: 7.30 for 8.00 in Port Vell (WTCB)